| Cat. No. |
Product Name |
Information |
| PC-38894 |
Sotrovimab
Anti-SARS-CoV-2 Spike mAb
|
Sotrovimab (VIR-7831, GSK4182136) is a human neutralizing monoclonal antibody with activity against SARS-CoV-2 sipke RBD. |
| PC-38893 |
Regdanvimab
Anti-SARS-CoV-2 Spike mAb
|
Regdanvimab (Regkirona, CT-P59) is a recombinant human immunoglobulin G1 antibody targeted against SARS-CoV-2 sipke RBD, shows therapeutic effect against SARS-CoV-2 South African variants. |
| PC-38891 |
Romlusevimab
Anti-SARS-CoV-2 Spike RBD mAb
|
Romlusevimab (BRII-198) is a fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of S (spike) protein of SARS-CoV-2. |
| PC-38890 |
Amubarvimab
Anti-SARS-CoV-2 Spike RBD mAb
|
Amubarvimab (BRII-196) is a fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of S (spike) protein of SARS-CoV-2. |
| PC-38888 |
Adintrevimab
Anti-SARS-CoV-2 Spike RBD mAb
|
Adintrevimab (ADG20) is a fully human IgG1 monoclonal antibody targeting the highly conserved epitope on the receptor-binding domain (RBD) of S (spike) protein of SARS-CoV-2. |
| PC-38882 |
Etesevimab
Anti-SARS-CoV-2 Spike mAb
|
Etesevimab (LY-CoV016, JS016) is a recombinant fully human monoclonal neutralizing antibody, specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain (RBD) with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. |
| PC-38879 |
Tixagevimab
Anti-SARS-CoV-2 Spike mAb
|
Tixagevimab (AZD8895) is a monoclonal antibody (mAb) against the SARS-CoV-2 spike protein, binds to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2, used in a combination of Tixagevimab/cilgavimab (AZD7442). |
| PC-38878 |
Cilgavimab
Anti-SARS-CoV-2 Spike mAb
|
Cilgavimab (AZD1061) is a monoclonal antibody (mAb) against the SARS-CoV-2 spike protein, binds to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2, used in a combination of Tixagevimab/cilgavimab (AZD7442). |
| PC-38877 |
Imdevimab
Anti-SARS-CoV-2 Spike mAb
|
Imdevimab (REGN10987) is a fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant mutant virus. |
| PC-38876 |
Casirivimab
Anti-SARS-CoV-2 Spike mAb
|
Casirivimab (REGN10933) is a fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant mutant virus. |
| PC-38875 |
Bamlanivimab
Anti-SARS-CoV-2 Spike mAb
|
Bamlanivimab (LY-CoV555) is a potent, recombinant, neutralizing human IgG1 monoclonal antibody (mAb) against the spike protein of SARS-CoV-2, binds to SARS-CoV-2 spike protein RBD and prevents its interaction with ACE2. |
| PC-Ab1121 |
Anti-SARS-CoV-2 Spike Protein (Omicron) mIgG1
|
. |
